Article
KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis.
Journal of the National Cancer Institute - 11 Apr 2022
Formica Vincenzo, Sera Francesco, Cremolini Chiara, Riondino Silvia, Morelli Cristina, Arkenau Hendrik-Tobias, Roselli Mario
Abstract excerpt
BACKGROUND: KRAS and BRAF mutations are well-established predictive and prognostic factors in metastatic colorectal cancer; however, their impact in the adjuvant setting has not yet been established. METHODS: We performed a meta-analysis of adjuvant phase III trials in patients with stage II and III colon cancer with available data on the impact of KRAS or BRAF mutations on both disease-free survival (DFS) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
